Kristen Hawthorne, MD
Ophthalmology · Austin, TXNPI 1003019092
Payments from drug & device makers
Across 140 payments — averaging $77.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Rxsight Inc$730
- Alcon$451
- Johnson & Johnson Surgical Vision, Inc.$334
- NEW World Medical,inc.$251
- Apellis Pharmaceuticals, Inc.$241
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$5,91354%
- Food & beverage$4,80244%
- Education$180%
- Entertainment$1441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $7,078 |
| Rxsight Inc | 7 | $730 |
| Alcon | 16 | $451 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $334 |
| NEW World Medical,inc. | 4 | $251 |
| Apellis Pharmaceuticals, Inc. | 2 | $241 |
| Glaukos Corporation | 2 | $237 |
| Bausch & Lomb Americas Inc. | 9 | $194 |
| Regeneron | 1 | $150 |
| Optos, Inc. | 1 | $144 |
| Sight Sciences, Inc. | 2 | $142 |
| Carl Zeiss Meditec, Inc. | 1 | $120 |
| Kala Pharmaceuticals, Inc. | 2 | $112 |
| Amgen(2 entities) | 6 | $110 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $103 |
| Dompe US, Inc. | 3 | $84 |
| Novartis | 4 | $77 |
| Sun Pharmaceutical Industries Inc. | 2 | $66 |
| Tarsus Pharmaceuticals, Inc. | 3 | $62 |
| Tearlab Corp | 4 | $55 |
| Biotissue Holdings Inc. | 2 | $47 |
| Harrow Eye, LLC | 1 | $20 |
| Thea Pharma Inc. | 1 | $18 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS MULTIDOSE$5,913
- RXSIGHT CONTACT LENS$583
- RXSIGHT INJECTOR CARTRIDGE$583
- RXSIGHT INJECTOR HANDPIECE$583
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$583
- LIGHT ADJUSTABLE LENS (LAL)$456
- PANORAMIC OPHTHALMOSCOPE$289
- OCT OPHTHALMOSCOPE$289
- Kahook Dual Blade$200
- Clearpath$200
- Ahmed Glaucoma Valve$200
- Streamline$200
- iDoseTR$165
- EYLEA HD$150
- NFC-700$144
- Centurion$143
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$127
- OMNI(R) SURGICAL SYSTEM (US)$127
- Syfovre$122
- IOLMaster$120
How this compares
$10,877 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 211 | $282,416 |
| ProlensaBromfenac Sodium | 234 | $80,250 |
| XiidraLifitegrast | 95 | $73,689 |
| Cyclosporine | 68 | $44,788 |
| RhopressaNetarsudil Mesylate | 48 | $39,585 |
| LumiganBimatoprost | 51 | $29,598 |
| Prednisolone Acetate | 746 | $24,009 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $22,058 |
| IlevroNepafenac | 43 | $15,995 |
| Bromfenac Sodium | 76 | $14,062 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 44 | $10,307 |
| Alphagan PBrimonidine Tartrate | 18 | $9,284 |
| Latanoprost | 735 | $9,072 |
| Ofloxacin | 617 | $8,374 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $8,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $7,078 | $343,356322 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $103 | $83,820262 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $194 | $80,549109 claims |
| NovartisIlevro | $77 | $15,99543 claims |
| AlconSimbrinza | $451 | $10,30744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Austin
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Shelley GhafooriAustin$2.9M
- Thomas WaltersAustin$2.4M
- Philip StoreyAustin$2.1M
- Saradha ChexalAustin$1.8M
- James DoonerAustin$556K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.